A higher expression of CD4+PD1+ cells in circulating peripheral blood mononuclear cells (PBMC) at baseline may predict a better response to tremelimumab treatment in HCC patients [100]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.